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BACKGROUND: TRIB3 is a human homologue of Drosophila tribbles. Previous studies have shown that TRIB3 controls the cell growth
through ubiquitination-dependent degradation of other proteins, whereas its significance in the prognosis of colorectal cancer (CRC)
is not yet fully understood.
MATERIALS: This study comprised 202 patients who underwent surgery for CRC, as well as 22 cell lines derived from human
gastrointestinal cancer. The correlation of gene expression with clinical parameters in patients was assessed. The biological significance
was evaluated by knockdown experiments in seven colorectal cancer cell lines.
RESULTS: A total of 20 cancer cell lines (90.9%) expressed the TRIB3 gene. The assessment in surgical specimens indicated that the
gene expression was significantly higher in the cancerous region than in the marginal non-cancerous region. Patients with high TRIB3
expression were statistically susceptible to a recurrence of the disease, and showed poorer overall survival than those with low
expression. The assessment of TRIB3 knockdown in five cell lines showed that small interfering RNA (siRNA) inhibition resulted in a
statistically significant reduction in cell growth.
CONCLUSION: These data strongly suggest the usefulness of TRIB3 as a marker for predicting the prognosis of CRC patients, showing a
basis for the development of effective treatments for CRC.
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In many developed countries, including the United States and
Japan, cancer is one of the most prominent illnesses in public
welfare and health measures (Jones et al, 2007; Jemal et al, 2008).
The incidence of colorectal cancer (CRC) has increased signi-
ficantly in recent years, in concert with the changing lifestyle
(Kohno et al, 2007). The major cause of death in CRC is liver
metastases (Yamasaki et al, 2007). Although treatment of CRC
has improved recently, it fails in approximately one-third of the
patients who need an alternative strategy for coping with death
(Jones et al, 2007). In this matter, useful predictive markers would
be desired in the medication of CRC patients.
As shown in other tumours, tumour-promoting oncogenes and
tumour suppressors control cell proliferation through cell-cycle
arrest of CRC (Aliaga et al, 1999; Jemal et al, 2008; Yamatodani
et al, 2009). Further identification of genes responsible for the
development and progression of CRC, as well as understanding of
their clinical significance, would lead to efficient diagnosis and
treatment of the disease. Characterization of key molecules is
particularly promising for the development of new approaches for
the treatment of gastrointestinal tumours.
Previous studies have shown that chromosomal aberrations
occur during carcinogenesis, and relate to patients’ prognoses in
CRC (Hermsen et al, 2002; Leslie et al, 2003). Alterations of
particular loci at chromosome 20 are reported, indicating the
significance of studies on this chromosomal region (Wang et al,
2001; Pledgie et al, 2005; Yde et al, 2007; Goodwin et al, 2008; Shor
et al, 2008). It has been shown that aberrant gains at chromosome
20 are specifically associated with mutations in the tumour
suppressor gene, TP53, by a survey of 50 cases of CRC, and they
are also correlated with the progression of CRC, suggesting that the
tumour suppressor pathway is involved in the maintenance of
particular chromosomal regions (Wang et al, 2001; Leslie et al,
2003; Pledgie et al, 2005; Yde et al, 2007; Goodwin et al, 2008; Shor
et al, 2008).
Although previous studies suggest candidate genes in the
regions at chromosome 20, which might have a role in CRC, it is
yet to be fully understood in prognostic value (Wu et al, 2006;
Zheng et al, 2008; Antonacopoulou et al, 2008). Here we report on
TRIB3 gene in the chromosomal region at 20p13, which is
overexpressed in CRC, as a new marker for prognosis and meta-
chronous metastasis. Trib3 is a human homologue of Drosophila
tribbles 3, which regulates cell growth, differentiation, oogenesis
and metabolism by promoting ubiquitination-dependent degrada-
tion of other proteins, interacts with several transcriptional factors
and is expressed in several tumours (Mata et al, 2000; Bowers et al,
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s2003; Du et al, 2003; Koo et al, 2004; Boudeau et al, 2006; He et al,
2006; Koh et al, 2006; Matsushima et al, 2006; Ord et al, 2007; Kato
and Du, 2007; Xu et al, 2007; Yao and Nyomba, 2008). We studied
the TRIB3 gene in 202 paired cancerous and non-cancerous
regions of CRC, as well as 7 colorectal cancer cell lines and 15 other
gastrointestinal cancer cell lines. Our data indicate the clinical
significance of TRIB3 in the evaluation of CRC prognosis.
MATERIALS AND METHODS
Cell lines and culture
A total of 22 cell lines derived from human CRC and other
gastrointestinal cancer (for CRC: Caco2, DLD-1, LoVo, HCT116,
HT-29, KM12SM and SW480; for oesophageal cancer: TE-5, TE-8
and TE-10; for gastric cancer: MKN28 and MKN45; for pancreatic
cancer: MIAPaCa-2, PANC-1 and PSN-1; for hepatocellular
carcinoma: HuH-7, HepG2, Hep3B, HLE, HLF and PLC; for
cholangiocellular carcinoma: HuCCT-1) were maintained in
Dulbecco’s modied Eagle’s medium containing 10% fetal bovine
serum and antibiotics at 371C in a 5% humidified CO2 atmosphere.
For small interfering RNA (siRNA) inhibition, double-stranded
RNA duplexes targeting human TRIB3 (50-GCGGUUGGAGUUGG
AUGACAACUUA-30 and 50-GCGUGAUCUCAAGCUGUGUCGCU
UU-30) were purchased as a Validated Stealth RNAi kit (Invitrogen,
Carlsbad, CA, USA), as well as negative control siRNA (12935-112,
Stealth RNAi Negative Control, Medium GC Duplex, Invitrogen).
CRC cell lines were transfected with siRNA at a concentration of
20mmolml
 1 using lipofectamine RNAiMAX (Invitrogen), incu-
bated in glucose-free Opti-MEM (Invitrogen) and analysed using
CellTac, a proliferation assay kit (Invitrogen). Values are presented
as means±s.d. from all independent experiments performed in
triplicate.
Clinical tissue samples
The study comprised 202 patients who underwent surgery for CRC,
including 118 patients at Kyusyu University from 1992 to 2002, and
84 patients at Osaka University from 2002 to 2006. Primary CRC
specimens and adjacent normal colorectal mucosa were obtained
from patients after written informed consent had been confirmed,
in accordance with institutional ethics guidelines. The surgical
specimens were fixed in formalin, processed through graded
ethanol and embedded in paraffin, and were sectioned with
haematoxylin and eosin staining (see the Supplementary Informa-
tion). For RNA study, all specimens were frozen immediately after
resection in liquid nitrogen and were kept at  801C until RNA
extractions. None of the patients received chemotherapy or
radiotherapy before surgery. After surgery, patients were followed
up with blood examinations including those for tumour markers,
such as serum carcinoembryonic antigen and cancer antigen
(CA19-9), and imaging modalities such as abdominal ultrasono-
graphy, computed tomography and chest X-ray every 3–6 months.
Clinico-pathological factors were assessed according to the criteria
of tumour–node–metastasis (TNM) classification of the Interna-
tional Union Against Cancer (UICC) (Sobin and Fleming, 1997).
RNA preparation and reverse transcriptase PCR (RT–PCR)
Total RNA was prepared using TRIzol reagent (Invitrogen) or with
DNase by a modified acid guanidium–phenol–choroform proce-
dure (Mimori et al, 1997). Reverse transcription was performed
with SuperScriptII (Invitrogen) or with 2.5mg of total RNA as
previously described (Mori et al, 1993). A 158-bp TRIB3 fragment
was amplified. Two human TRIB3 oligonucleotide primers for the
PCR reaction were designed as follows: 50-TGCCCTACAGGC
ACTGAGTA-30 (forward); 50-GTCCGAGTGAAAAAGGCGTA-30
(reverse). The forward primer is located in exon 2 and the reverse
primer in exon 3. To confirm PCR amplification, 25–35 cycles of
PCR reaction were performed using a PCR kit (Takara, Kyoto,
Japan) on a Geneamp PCR system 9600 (PE Applied Biosystems,
Foster City, CA, USA) with the following parameters: 951C for 10s,
601C for 10s and 721C for 60s. An 8-ml aliquot of each reaction
mixture was size-fractionated in a 1.5% agarose gel and visualised
using ethidium bromide staining. To confirm RNA quality, a PCR
amplification of 270bp was performed for the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene using the following
primers: 50-TTGGTATCGTGGAAGGACTCA-30 and 50-TGTCAT
CATATTGGCAGGTT-30. Human reference complementary DNAs
were used as positive controls (Clontech).
Quantitative real-time RT–PCR
For quantitative assessment, quantitative real-time RT–PCR was
performed using a kit, LightCycler FastStart DNA Master SYBR
Green I (Roche Diagnostics, Tokyo, Japan), for PCR amplification
of TRIB3 and GAPDH. The amplification protocol consisted of
denaturation at 951C for 10s, annealing at 601C for 10s and
elongation at 721C for 10s. The products were then subjected
to a temperature gradient from 55 to 951C with continuous
fluorescence monitoring to produce a melting curve of the
products. The expression ratios of mRNA copies in tumour and
normal tissues were calculated to normalise against GAPDH
mRNA expression.
Immunohistochemistry
A total of 20 cases of CRC surgical specimens from formalin-fixed,
paraffin-embedded tissues were used for Trib3 immunohisto-
chemistry. After deparaffinization and blocking, the antigen–
antibody complex was incubated overnight at 41C. ENVISION
reagents (Dako Cytomation, Glostrup, Denmark) were used to
detect the signal from the antigen–antibody reaction. All sections
were counterstained with haematoxylin. The primary anti-Trib3
rabbit polyclonal antibody (HPA015272; Sigma, St Louis, MO,
USA) was used at a dilution of 1:100. All sections were
independently examined for protein expression, and assessed by
comparison of staining between normal and cancer regions under
microscopic examination of X100 fields in each specimen.
Proliferation assay
To determine the proliferative properties, 1.0 10
5 cells were
seeded and cultured into each 24-well dish. The cell growth rate
was measured by counting cells using a CellTac kit (Nihon Koden,
Tokyo, Japan).
Statistical analysis
For continuous variables, data are expressed as mean±s.d. The
relationship between TRIB3 expression and clinico-pathological
factors was analysed using w
2 and Student’s t-tests. Kaplan–Meier
survival curves were plotted and compared with the generalised
log-rank test. Univariate and multivariate analyses for the
identification of prognostic factors were performed using a Cox
proportional hazard regression model. All tests were analysed
using JMP software (SAS Institute, Cary, NC, USA). Differences
with P-values o0.05 were considered statistically significant.
RESULTS
Expression of TRIB3 in CRC cell lines and clinical tissue
specimens
We first studied the expression of TRIB3 gene, and evaluated it
in gastrointestinal cancer cell lines and clinical tissue samples
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was specific and produced a single band in agarose gel, stained
with ethidium bromide, before performing real-time PCR. The
RT–PCR study of TRIB3 in 22 human gastrointestinal cancer lines
indicated 20 cells (90.9%; TE-8, TE-10, MKN45, MIAPaCa-2,
PANC-1, PSN-1, HuH-7, HepG2, Hep3B, HLE, HLF, PLC,
HuCCT-1, Caco2, DLD-1, LoVo, HCT116, HT-29, KM12SM and
SW480) that expressed the TRIB3 gene with a band in gel (the
Supplementary Figure S1A). The RT–PCR analysis of TRIB3 in
primary CRC samples was then performed in paired normal
and tumour samples (representative data shown in Supple-
mentary Figure S1B: TRIB3 expression was higher in cancerous
regions than in normal regions). Quantitative real-time RT–PCR
on 202 paired cancer and normal samples showed that 181 of
202 (89.6%) samples had higher levels of TRIB3 mRNA in
cancerous regions than in normal regions (Figure 1). The mean
expression value of TRIB3 mRNA in cancerous regions (normal-
ised by GAPDH gene expression) was significantly higher than
the value in the corresponding normal regions (Po0.001; Student’s
t-test).
Expression of Trib3 protein
Figure 2 shows a representative immunohistochemical staining
pattern for Trib3 in tissue from a CRC patient. Trib3 protein
staining was observed in the nucleus and cytoplasm in epithelial
cells; the expression of CRC was compared with non-cancerous
epithelial cells, whereas the expression was appreciably weak or
hardly detectable in stromal cells. Examination of 20 cases, which
were selected randomly, indicated that 16 cases showed a higher
expression level of Trib3 protein in cancerous regions compared
with normal regions, whereas the remaining four cases showed no
difference between normal and cancerous regions. To compare the
data, mRNA expression was assessed by gel RT–PCR and real-time
RT–PCR. The data show that mRNA expression was high level in
all 16 immunohistochemistry-positive tumours, whereas mRNA
expression was comparable in normal and cancerous regions of the
remaining four tumours, suggesting that the high expression
of Trib3 protein is associated with mRNA expression (Po0.001;
w
2 test). No variation of staining intensity for Trib3 was observed
in each of the specimens. We concluded that both mRNA and the
protein coded by this gene are associated and frequently expressed
together in CRC.
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Figure 1 TRIB3 mRNA expression in clinical tissue specimens.
Quantitative real-time RT–PCR on 202 paired clinical samples showed
that 181 of 202 (89.6%) samples had higher levels of TRIB3 mRNA
in tumours than in paired normal regions. The mean expression value
of TRIB3 mRNA in tumour regions, 154.62±1021.63 (mean±s.d.;
normalised by GAPDH gene expression), was significantly higher than the
value, 6.98±4.91, for the corresponding normal regions (Po0.001;
Student’s t-test). GAPDH¼glyceraldehydes-3-phosphate dehydrogenase;
RT–PCR¼ reverse transcriptase PCR; TRIB3¼tribbles homologue 3.
Figure 2 Immunohistochemical staining for Trib3 in tumour and normal
specimens. A representative positive stain for Trib3 in tissues from CRC
patients. Positive staining is observed in the nucleus and cytoplasm of
cancer cells, but not in stromal cells. Trib3 expression was associated with
mRNA expression. CRC¼colorectal cancer; T¼tumour cells; N¼normal
glandular cells. Bar¼200mm (original magnification,  20).
Table 1 Clinicopahological factors and TRIB3 mRNA expression in 202
colorectal cancers
High expression Low expression
Factors (%) (%) P-value
Age (years)
p67 45 (44.5) 51 (50.5) 0.397
67o 56 (55.5) 50 (49.5)
Gender
Male 63 (62.4) 52 (51.5) 0.118
Female 38 (37.6) 49 (48.5)
Histological grade
Wel-Mod 95 (94.1) 89 (88.1) 0.138
Others 6 (5.9) 12 (11.9)
Tumour size (mm)
p30 24 (23.8) 22 (21.8) 0.737
30o 77 (76.2) 79 (78.2)
Tumour invasion
Tis 5 (5.0) 10 (9.9) 0.418
T1 6 (5.9) 11 (10.9)
T2 20 (19.8) 19 (18.8)
T3 49 (48.5) 44 (43.6)
T4 21 (20.8) 17 (16.8)
Lymph node metastasis
N0 60 (59.4) 61 (60.4) 0.885
N1–2 41 (40.6) 40 (36.6)
Lymphatic invasion
Absent 49 (48.5) 51 (50.5) 0.778
Present 52 (51.5) 50 (49.5)
Venous invasion
Absent 78 (77.2) 74 (73.3) 0.514
Present 23 (22.8) 27 (26.7)
Metastasis
M0 68 (67.3) 90 (89.1) o0.001
M1 33 (32.7) 12 (10.9)
Wel¼well differentiated adenocarcinoma; Mod¼moderately differentiated adeno-
carcinoma; Others¼poorly differentiated adenocaricinoma and mucinous carcinoma;
TRIB3 tribbles homologue 3. The statistic significance is shown with under line.
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To study the TRIB3 expression in CRC quantitatively, the data
were classified into two experimental groups on the basis of the
TRIB3 expression levels to assess the expression value without any
bias. The high-expression group comprised patients who had a
level of TRIB3 expression higher than the median value for TRIB3/
GAPDH expression in tumour regions compared with normal
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Figure 3 Overall survival rates of patients with CRC on the basis
of TRIB3 mRNA expression status. The overall survival rate was signi-
ficantly lower in the TRIB3 high-expression group than that in the low-
expression group (Po0.001). CRC¼colorectal cancer; TRIB3¼tribbles
homologue 3.
Table 2 Univariate and multivariate analysis for overall survival (Cox
proportional hazards regression model)
Univariate
analysis
Multivariate
analysis
Factors RR 95% CI P-value RR 95% CI P-value
Age(years)
(p67/67o) 1.23 0.85–1.80 0.258
Gender
(Male / female) 1.93 0.90–4.47 0.090
Histological grade
(Wel-Mod / others) 1.54 0.36–4.35 0.511
Tumour size
(30o/p30) 3.70 1.69–15.66 0.001 2.04 0.88–8.79 0.103
Tumour invasion
(T3–4 / Tis-2) 11.00 3.28–68.37 o0.001 2.47 0.60–16.82 0.223
Lymph node metastasis
(N1–2 / N0) 4.28 2.02–9.63 0.001 1.49 0.65–3.74 0.348
Lymphatic invasion
(Present / absent) 2.44 1.14–5.44 0.021 1.43 0.62–3.49 0.396
Venous invasion
(Present / absent) 2.17 0.92–4.73 0.071
Metastasis
(M1 / M0) 21.89 9.33–60.11 o0.001 9.34 3.70–27.28 o0.001
TRIB3 mRNA expression
(mediano / omedian) 8.45 2.97–35.48 o0.001 3.78 1.27–16.35 0.014
RR¼relative risk; CI¼confidence interval; Wel¼well differentiated adenocarcinoma;
Mod¼moderately differentiated adenocarcinoma; Others¼poorly differentiated
adenocaricinoma and mucinous carcinoma; TRIB3 tribbles homologue 3.
The statistic significance is shown with under lines.
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Figure 4 Metachronous metastasis-free over 5 years’ survival rates of
patients with CRC in stages I II, and III, on the basis of TRIB3 mRNA
expression status. The metachronous metastasis-free over 5 years’ survival
rate was significantly lower in patients with the TRIB3 high-expression group
compared with the low-expression group (P¼0.007). CRC¼colorectal
cancer; TRIB3¼tribbles homologue 3.
Table 3 Univariate and multivariate analysis for metachronous metas-
tasis-free over 5 years survival rate (Cox proportional hazards regression
model)
Univariate
analysis
Multivariate
analysis
Factors RR 95% CI P-value RR 95% CI P-value
Age(years)
(67o/p67) 1.33 0.85–2.09 0.202
Gender
(Male / female) 2.44 0.97–6.90 0.055
Histological grade
(Wel-Mod / others) 24.0 4.78–101.61 o0.001 25.9 3.57–215.84 0.001
Tumor size
(30o / p30) 3.66 1.66–15.55 o0.001 3.04 1.18–13.62 0.017
Tumor invasion
(T3–4 / Tis-2) 4.80 1.61–20.58 0.003 2.77 0.67–15.00 0.160
Lymph node
metastasis
(N1–2 / N0) 4.01 1.65–10.26 0.002 2.65 0.98–7.59 0.054
Lymphatic invasion
(Present / absent) 4.49 1.73–13.83 0.001 0.72 0.20–2.95 0.637
Venous invasion
(Present / absent) 3.10 1.21–7.53 0.019 1.68 0.61–4.53 0.301
TRIB3 mRNA
expression
(mediano /
pmedian)
4.33 1.45–18.59 0.006 3.86 1.09–19.00 0.035
RR¼relative risk; CI¼confidence interval; Wel¼well differentiated adenocarci-
noma; Mod¼moderately differentiated adenocarcinoma; Others¼poorly differen-
tiated adenocaricinoma and mucinous carcinoma; TRIB3 tribbles homologue 3.
The statistic significance is shown with under lines.
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sregions (n¼101); other patients were assigned to the low-
expression group (n¼101). Clinico-pathological factors related
to TRIB3 expression status are shown in Table 1. Data indicated
that metastasis (M0 / M1) was correlated with TRIB3 expression
(Po0.001). The metastatic sites were the liver (37 cases), lung
(10 cases), brain (3 cases) and bone (1 case). Metastatic sites and
other factors were not significantly correlated with TRIB3
expression.
Relationship between TRIB3 expression and prognosis
The study of prognosis revealed that the overall survival rate
was significantly lower for patients in the high-expression
group (Po0.001; Figure 3). The median follow-up was 2.98 years.
Table 2 shows the univariate and multivariate analyses of
factors related to patient prognosis. Univariate analysis showed
that the post-operative overall survival was significantly correlated
with following factors: tumour size (P¼0.001), tumour inva-
sion (Po0.001), lymph node metastasis (P¼0.001), lymphatic
invasion (P¼0.021), metastasis (Po0.001) and TRIB3 expression
(Po0.001). Multivariate regression analysis indicated that
an inclusion in the TRIB3 high-expression group (relative risk
(RR)¼3.78; 95% confidence interval (CI)¼1.27–16.35; P¼0.014)
was an independent predictor of overall survival, as was meta-
stasis (M1 / M0) (RR¼9.34; 95% CI¼3.70–27.28; Po0.001),
indicating a significant link between TRIB3 expression and patient
prognosis.
In 65 of 202 patients, we have followed up over 5 years after
the primary operation, the median follow-up was 6.31 years. We
then evaluated the metachronous, metastasis-free, over 5years’
survival in these patients, indicating that the rate was significantly
lower in patients of the high-expression group (P¼0.007, Figure 4).
Table 3 shows the univariate and multivariate analyses of
factors related to patient prognosis. Univariate analysis showed
that the post-operative metastasis was significantly correlated
with following factors: histological grade (Po0.001), tumour size
(Po0.001), tumour invasion (P¼0.003), lymph node metastasis
(P¼0.001), lymphatic invasion (P¼0.001), venous invasion
(P¼0.019) and TRIB3 mRNA expression (P¼0.006). Multi-
variate regression analysis indicated that inclusion in the
TRIB3 high-expression group (RR¼3.86; 95% CI¼1.09–19.00;
P¼0.035) was an independent predictor of metastasis-free
survival, as were histological grade (RR¼25.9; 95% CI¼
3.57–215.84; P¼0.001) and tumour size (RR¼3.04; 95% CI¼
1.18–13.62; P¼0.017).
Effect of TRIB3 inhibition in CRC cell growth
A total of 7 CRC cell lines were subjected to siRNA knockdown.
The biological role of TRIB3 in vitro was analysed in CRC, in which
TRIB3 expression was knocked down. In the CRC cell lines
examined, significant suppression of endogenous TRIB3 expres-
sion by siRNA was confirmed by real-time RT–PCR in five cell
lines (DLD-1, LoVo, HCT116, KM12SM and SW480; Po0.05,
Student’s t-test; Supplementary Figure S2). To determine the
proliferative properties, cells were seeded and cultured (Figure 5).
There were significant differences in numbers between wild-type
or negative control and TRIB3 siRNA (Po0.05) in all five CRC cell
lines. There was no significant change in number between negative
control and wild type.
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Figure 5 Proliferation assay with siRNA inhibition in five CRC cell lines. Proliferation assay was performed in five CRC cell lines (A, DLD-1; B, LoVo;
C, HCT-116; D, KM12SM; E, SW480). There were significant differences between WT or NC, and TRIB3 siRNA. Values are presented means±s.d. of three
independent experiments. CRC¼colorectal cancer; NC¼negative control; TRIB3¼tribbles homologue 3; WT¼wild type.
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This study showed that TRIB3 is expressed at higher levels in CRC
than in the corresponding normal regions, and is expressed in
gastrointestinal cancer cell lines. The siRNA inhibition experiment
showed the functional relevance of expressed TRIB3 in gastro-
intestinal cancer cell lines. To the best of our knowledge, this study
is the first to show the candidacy of TRIB3 as a prognostic CRC
marker, supported by the functional relevance to cell growth.
Nowadays, it can be useful to determine the necessity of
intensive follow-up and adjuvant therapy for CRC by predicting
recurrence and metastases in curative surgical resection (Bathe
et al, 2004; Kornmann et al, 2008; Wolpin and Mayer, 2008). In this
study, clinico-pathological analysis revealed that TRIB3 is closely
related to metastasis, but not to lymphatic metastasis. It may
correlate with some mechanism of little concern to invasiveness.
Patients with CRCs with high TRIB3 expression showed a poorer
prognosis for disease-free and overall survival than those in the
low-expression group. Data indicate that TRIB3 is an independent
prognostic factor, as well as a very important predictor that is
already known (Derkinderen et al, 1990). TRIB3 is presumably a
good predictor of metachronous metastasis that can be followed by
curative surgical intervention. In gastrointestinal cancer therapy, it
is essential to prevent metachronous metastasis. Several adjuvant
chemotherapies are helpful in certain disease stages, especially in
CRC (Bathe et al, 2004; Andre et al, 2007). Recently, increasing
evidence has been accumulated, showing the usefulness of less
invasive surgery in the treatment of CRC, such as laparoscopic and
endoscopic surgery (Lacy et al, 2002; Weeks et al, 2002; Clinical
Outcomes of Surgical Therapy Study Group, 2004; Jayne et al,
2007). For these cases, predictive markers of tumour invasion and
metastasis, which are independent of traditional TNM classifica-
tion and contribute collectively to diagnoses and treatments, are
very important. These data indicate the candidacy of TRIB3.
Although improving treatments such as pre-operative and
post-operative chemotherapy and radiotherapy combined with
surgery for CRC have contributed to the reduction of recurrences
and metastases, half of the cases eventually metastasise despite
systemic chemotherapy followed by surgery (Koshariya et al,
2007). Adjuvant chemotherapy for CRC has been desirable in
highly suspicious metastatic cases. In these cases, the assessment
of TRIB3 expression may be useful to predict patient prognosis.
In biological assessment, this study showed that TRIB3
expression was related to tumour growth in several gastrointestinal
cancer cell lines. The in vivo study showed that siRNA inhibition of
TRIB3 resulted in a reduction in cell growth of seven gastro-
intestinal cancer cell lines, significantly (Po0.05). Although
previous reports showed that TRIB3 is expressed in several cancer
cell lines, this study shows that TRIB3 seems to stimulate
proliferation, and may be a new target for the therapy of
gastrointestinal cancer (Bowers et al, 2003; Xu et al, 2007).
Tribs, belong to the pseudokinase family consisting of three
mammalian isoforms, Trib1, Trib2 and Trib3, have no detectable
kinase catalytic activity because of variations in key amino acids in
the ATP-binding domain, but possess substrate-binding domains
relating to their function as protein-interacting modules (Seher
and Leptin, 2000; Yamatodani et al, 2009). Tribs associate with
large proteins such as transcriptional factors, and regulate cell
growth, differentiation and metabolism (Boudeau et al, 2006).
Trib1 interacts with Mapk and modulates Mapkk activity
associated with smooth muscle cell proliferation and migration
(Kiss-Toth et al, 2004; Sung et al, 2007). Trib2 has a role in
adipogenesis in combination with the degradation of C/EBPbeta
(Naiki et al, 2007). Trib3 promotes ubiquitination and degradation
of proteins involved in cell-cycle regulation and oogenesis through
an interaction with activation transcription factor 4, and is
involved in the Pten pathway through interaction with Akt (Mata
et al, 2000; Du et al, 2003; He et al, 2006; Koh et al, 2006; Kato and
Du, 2007; Yao and Nyomba, 2008). Trib3 expression is increased in
several primary tumours and cancer cell lines and can be
controlled by nutrient starvation, which is consistent with these
data (Bowers et al, 2003; Schwarzer et al, 2006; Xu et al, 2007). Our
report indicates that TRIB3 is not only a new independent
prognostic factor and predictor of metachronous metastasis, but is
also a useful target because the inhibition of TRIB3 may lead to the
reduction of CRC through the control of cell growth.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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